Molecular markers in bladder cancer: Novel research frontiers

Critical Reviews in Clinical Laboratory Sciences

Volumn 52, Issue 5, 2015, Pages 242-255

  Sanguedolce, Francesca ^a   Cormio, Antonella ^b   Bufo, Pantaleo ^a   Carrieri, Giuseppe ^a   Cormio, Luigi ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Molecular biology; pathology; statistical analysis; urinary malignancy

Indexed keywords

HORMONE RECEPTOR; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOCHONDRIAL DNA; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN; TELOMERASE; TUMOR MARKER; UROKINASE; BIOLOGICAL MARKER;

BLADDER CANCER; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK ASSESSMENT; URINE; BLOOD; EVIDENCE BASED MEDICINE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; PROGNOSIS; URINARY BLADDER NEOPLASMS;

BIOMARKERS; EPIGENESIS, GENETIC; EVIDENCE-BASED MEDICINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84941620978     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2015.1033610     Document Type: Review

References (264)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, Lyon, France: International Agency for Research on Cancer, 2010.
2. Sanguedolce F, Bufo P, Carrieri G, Cormio L. Predictive markers in bladder cancer. Do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 2014:1-14.
3. Babjuk M, Burger M, Zigeuner R, et al. Guidelines on Non-muscle Invasive Bladder Cancer (TaT1 and CIS). London: European Association of Urology; 2013.
4. Witjes JA, Comperat E, Cowan NC, et al. Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. London: European Association of Urology; 2013.
5. Shah JB, McConkey DJ, Dinney PN. New strategies in muscleinvasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 2011;17:2608-12.
6. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5.
7. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182:2195-203.
8. Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013;109:1460-6.
9. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118-25.
10. Van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58: 433-41.
11. Alkhateeb SS, Neill M, Bar-Moshe S, et al. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urol Ann 2011; 3:119-26.
12. Goodison S, Rosser CJ, Urquidi V. Bladder cancer detection and monitoring: assessment of urine-and blood-based marker tests. Mol Diagn Ther 2013;17:71-84.
13. Rink M, Cha EK, Green D, et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012;13:122-35.
14. Butt AJ, Firth SM, Baxter RC. The IGF axis and programmed cell death. Immunol Cell Biol 1999;77:256-62.
15. Shariat SF, Kim J, Nguyen C, et al. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology 2003;61: 359-64.
16. Miyake H, Hara I, Yamanaka K, et al. Prognostic significance of insulin-like growth factor (IGF) binding protein-2 to IGF-binding protein-3 ratio in patients undergoing radical cystectomy for invasive transitional cell carcinoma of the bladder. BJU Int 2005; 95:987-91.
17. Eder IE, Stenzl A, Hobisch A, et al. Transforming growth factorsbeta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol 1996;156:953-7.
18. Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001;92: 2985-92.
19. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
20. Ito TK, Ishii G, Saito S, et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009;113:2363-9.
21. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-52.
22. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
23. Gohji K, Fujimoto N, Fujii A, et al. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 1996;56:3196-8.
24. Hudson MA, McReynolds LM. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 1997;89:709-17.
25. Shariat SF, Monoski MA, Andrews B, et al. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 2003;61:1053-8.
26. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997;72:149-54.
27. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-5.
28. Matsumoto K, Shariat SF, Casella R, et al. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol 2003;170:2248-52.
29. Veltri RW, Makarov DV. Nucleic acid-based marker approaches to urologic cancers. Urol Oncol 2006;24:510-27.
30. Guzzo TJ, McNeil BK, Bivalacqua TJ, et al. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol 2012;30:44-8.
31. Gallagher DJ, Milowsky MI, Ishill N, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 2009;20:305-8.
32. Gradilone A, Petracca A, Nicolazzo C, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int 2010;106:710-15.
33. Rink M, Chun FK, Minner S, et al. Detection of circulating tumour cells in peripheral blood of patients with advanced nonmetastatic bladder cancer. BJU Int 2011;107:1668-75.
34. Fujii Y, Kageyama Y, Kawakami S, et al. Detection of disseminated urothelial cancer cells in peripheral venous blood by a cytokeratin 20-specific nested reverse transcriptasepolymerase chain reaction. Jpn J Cancer Res 1999;90:753-7.
35. Li SM, Zhang ZT, Chan S, et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol 1999;162:931-5.
36. Lu JJ, Kakehi Y, Takahashi T, et al. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res 2000;6:3166-71.
37. Osman I, Kang M, Lee A, et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer 2004;111:934-9.
38. Gazzaniga P, Gandini O, Giuliani L, et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res 2001;7:577-83.
39. Okegawa T, Kinjo M, Horie S, et al. Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology 2003;62:182-6.
40. Kinjo M, Okegawa T, Horie S, et al. Detection of circulating MUC7-positive cells by reverse transcription polymerase chain reaction in bladder cancer patients. Int J Urol 2004;11:38-43.
41. Okegawa T, Hayashi K, Hara H, et al. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol 2010;17:254-8.
42. Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer 2011;11:336.
43. Nezos A, Msaouel P, Pissimissis N, et al. Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev 2010;37:284-90.
44. Birkhahn M, Mitra AP, Williams AJ, et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010;57:12-20.
45. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64.
46. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 2003;89:2172-7.
47. Sanchez-Carbayo M, Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007; 34:75-84.
48. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002;62:6973-80.
49. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89.
50. Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011;42:455-81.
51. Mengual L, Burset M, Ribal MJ, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res 2010;16:2624-33.
52. Heidenblad M, Lindgren D, Jonson T, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008;1:3.
53. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463-72.
54. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685-96.
55. Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009;27:3929-37.
56. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42:978-84.
57. Serizawa RR, Ralfkiaer U, Steven K, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer 2011;129:78-87.
58. Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur Urol 2001;40:231-8.
59. Shirodkar SP, Lokeshwar VB. Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol 2009;19: 488-93.
60. Modlich O, Prisack HB, Pitschke G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004;10:3410-21.
61. Hartmann A, Rosner U, Schlake G, et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest 2000;80:709-18.
62. Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin bladder cancer. N Engl J Med 1992;326:737-40.
63. Dyrskjot L. Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics. Expert Rev Mol Diagn 2003;3:635-47.
64. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33:90-6.
65. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11:4044-55.
66. Dyrskjot L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13: 3545-51.
67. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatincontaining chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007;13:4407-14.
68. Zieger K, Dyrskjot L, Wiuf C, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005;11:7709-19.
69. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-36.
70. Havaleshko DM, Cho H, Conaway M, et al. Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther 2007;6:578-86.
71. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007;104:13086-91.
72. Savas S, Liu G. Genetic variations as cancer prognostic markers. Hum Mutat 2009;30:1369-77.
73. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
74. Jeronimo C, Nomoto S, Caballero OL, et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001;20:5195-8.
75. Guerra F, Kurelac I, Cormio A, et al. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet 2011;20:2394-405.
76. Nomoto S, Yamashita K, Koshikawa K, et al. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res 2002;8:481-7.
77. Chen GF, Chan FL, Hong BF, et al. Mitochondrial DNA mutations in chemical carcinogen-induced rat bladder and human bladder cancer. Oncol Rep 2004;12:463-72.
78. Guney AI, Ergec DS, Tavukcu HH, et al. Detection of mitochondrial DNA mutations in nonmuscle invasive bladder cancer. Genet Test Mol Biomarkers 2012;16:672-8.
79. Maitra A, Cohen Y, Gillespie SE, et al. The human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 2004;14:812-19.
80. Jakupciak JP, Maragh S, Markowitz ME, et al. Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer 2008;8:285.
81. Shakhssalim N, Houshmand M, Kamalidehghan B, et al. The mitochondrial C16069T polymorphism, not mitochondrial D310 (D-loop) mononucleotide sequence variations, is associated with bladder cancer. Cancer Cell Int 2013;13:120-128.
82. Parrella P, Seripa D, Matera MG, et al. Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett 2003;190:73-7.
83. Goessl C, Muller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 2002;41:668-76.
84. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017-19.
85. Jakupciak JP, Maragh S, Markowitz ME, et al. Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer 2008;8:285.
86. Ellinger J, Müller DC, Müller SC, et al. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol 2012;30:509-15.
87. Rivas A, Burzio V, Landerer E, et al. Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancer. BMC Urol 2012;12:37.
88. Guo X, Chen KH, Guo Y, et al. Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ Res 2007;101:1113-22.
89. Wang W, Lu J, Zhu F, et al. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med Oncol 2012;29:70-6.
90. Corrado M, Scorrano L, Campello S. Mitochondrial dynamics in cancer and neurodegenerative and neuroinflammatory diseases. Int J Cell Biol 2012;2012:729290.
91. Jin B, Fu G, Pan H, et al. Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol 2011;28:S373-80.
92. Straub B, Muller M, Krause H, et al. Molecular staging of pelvic surgical margins after radical prostatectomy: comparison of RTPCR for prostate-specific antigen and telomerase activity. Oncol Rep 2002;9:545-9.
93. Lin Y, Miyamoto H, Fujinami K, et al. Telomerase activity in human bladder cancer. Clin Cancer Res 1996;2:929-32.
94. Kyo S, Kunimi K, Uchibayashi T, et al. Telomerase activity in human urothelial tumors. Am J Clin Pathol 1997;107:555-60.
95. Muller H, Heine B, Heicappell R, et al. Telomerase activity in bladder cancer, bladder washings and in urine. Int J Oncol 1996;9: 1169-73.
96. Kinoshita H, Ogawa O, Kakehi Y, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89:724-30.
97. Fedriga R, Gunelli R, Nanni O, et al. Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. Neoplasia 2001;3:446-50.
98. Yoshida K, Sugino T, Tahara H, et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79: 362-9.
99. Wu WJ, Liu LT, Huang CH, et al. Telomerase activity in human bladder tumors and bladder washing specimens. Kaohsiung J Med Sci 2001;17:602-9.
100. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005;294: 2052-6.
101. Landman J, Chang Y, Kavaler E, et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402.
102. Saad A, Hanbury DC, McNicholas TA, et al. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-73.
103. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161:388-94.
104. Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002; 167:2001-6.
105. Muller M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002;21:650-5.
106. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001;166:666-73.
107. Arai Y, Yajima T, Yagihashi A, et al. Limitations of urinary telomerase activity measurement in urothelial cancer. Clin Chim Acta 2000;296:35-44.
108. Neves M, Ciofu C, Larousserie F, et al. Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol 2002;167: 1276-81.
109. Fukui T, Nonomura N, Tokizane T, et al. Clinical evaluation of human telomerase catalytic subunit in bladder washings from patients with bladder cancer. Mol Urol 2001;5:19-23.
110. Brems-Eskildsen AS, Zieger K, Toldbod H, et al. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer 2010;10:646.
111. Mucciardi G, Gali A, Barresi V, et al. Telomere instability in papillary bladder urothelial carcinomas: comparison with grading and risk of recurrence. Indian J Urol 2014;30:245-51.
112. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 2008;99:1528-38.
113. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339: 957-9.
114. Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA 2013;110:17426-31.
115. Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 2013;73: 7162-7.
116. Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6.
117. Netto GJ. Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "Mirage"?. Adv Anat Pathol 2013;20:175-203.
118. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009;4:251-85.
119. Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5:e13821.
120. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006;66:7401-4.
121. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80: 904-8.
122. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998;16:3215-18.
123. Wang DS, Rieger-Christ K, Latini JM, et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 2000;88:620-5.
124. Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009;15:6008-17.
125. Chen M, Gu J, Delclos GL, et al. Genetic variations of the PI3KAKT-mTOR pathway and clinical outcome in muscle-invasive and metastatic bladder cancer patients. Carcinogenesis 2010;31: 1387-91.
126. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011;58:1054-63.
127. Korkolopoulou P, Levidou G, Trigka EA, et al. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 2012;110:E1237-48.
128. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:121-30.
129. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
130. Homma N, Tamura G, Honda T, et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci 2006;97: 51-6.
131. Tozawa T, Tamura G, Honda T, et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 2004;95:736-40.
132. Uematsu F, Takahashi M, Yoshida M, et al. Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci 2006;97:611-17.
133. Chung W, Bondaruk J, Jelinek J, et al. Detection of Bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prevent 2011;20: 1483-91.
134. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005;23: 2903-10.
135. Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 2005;65:9347-54.
136. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-63.
137. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007;13:2046-53.
138. Jarmalaite S, Jankevicius F, Kurgonaite K, et al. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 2008;75:145-51.
139. Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics 2011;3:19-34.
140. Dudziec E, Goepel JR, Catto JW. Global epigenetic profiling in bladder cancer. Epigenomics 2011;3:35-45.
141. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10:7457-65.
142. Muto S, Horie S, Takahashi S, et al. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 2000;60:4021-5.
143. Kim EJ, Kim YJ, Jeong PD, et al. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol 2008;180:1141-5.
144. Dulaimi E, Uzzo RG, Greenberg RE, et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93.
145. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70.
146. Frantzi M, Makridakis M, Vlahou A. Biomarkers for bladder cancer aggressiveness. Curr Opin Urol 2012;22:390-6.
147. Nishiyama N, Arai E, Chihara Y, et al. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci 2010;101:231-40.
148. Lin HH, Ke HL, Huang SP, et al. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol 2010;28:597-602.
149. Vinci S, Giannarini G, Selli C, et al. Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urol Oncol 2011;29:150-6.
150. Cabello MJ, Grau L, Franco N, et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn 2011;13:29-40.
151. Vallot C, Stransky N, Bernard-Pierrot I, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011;103:47-60.
152. Dudziec E, Miah S, Choudhry H, et al. Hypermethylation of CpG Islands and shores around specific MicroRNAs and Mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 2011;17:1287-96.
153. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128:1327-34.
154. Yates DR, Rehman I, Meuth M, et al. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006;25:1984-8.
155. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004.
156. Casadio V, Molinari C, Calistri D, et al. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Cancer Res 2013;32:94.
157. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
158. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
159. Balmain A. Cancer: new-age tumour suppressors. Nature 2002; 417:235-7.
160. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007;8:286-98.
161. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39:457-66.
162. Agundez M, Grau L, Palou J, et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours. Eur Urol 2011;60:131-40.
163. Ha YS, Jeong P, Kim JS, et al. Tumorigenic and prognostic significance of RASSF1A expression in Low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer. Urology 2012; 79:1411.e1-e6.
164. Khin SS, Kitazawa R, Win N, et al. BAMBI gene is epigenetically silenced in subset of high-grade bladder cancer. Int J Cancer 2009;125:328-38.
165. Kunze E, Wendt M, Schlott T. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. Int J Mol Med 2006; 18:547-57.
166. Alvarez-Múgica M, Cebrian V, Fernández-Gómez JM, et al. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol 2010;184:1507-13.
167. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013;93:98-104.
168. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
169. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
170. Dyrskjot L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009;69: 4851-60.
171. Han Y, Chen J, Zhao X, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011;6: e18286.
172. Yun SJ, Jeong P, Kim WT, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012;41:1871-8.
173. Snowdon J, Boag S, Feilotter H, et al. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J 2012;15:1-5.
174. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 2012;180: 1808-15.
175. Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011;102:522-9.
176. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010;28:655-61.
177. Miah S, Dudziec E, Drayton RM, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012;107:123-8.
178. Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2013;31:1701-8.
179. Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res 2009; 69:8472-81.
180. Pignot G, Cizeron-Clairac G, Vacher S, et al. MicroRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 2013;132:2479-91.
181. Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A microRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 2011;29:794-801.
182. Yang H, Dinney CP, Ye Y, et al. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008;68:2530-7.
183. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009;124: 2236-42.
184. Yoshino H, Seki N, Itesako T, et al. Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol 2013;10:396-404.
185. Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, et al. MiRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 2012;5:40.
186. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158: 1491-502.
187. Goodison S, Chang M, Dai Y, et al. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One 2012;7: e47469.
188. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol 1996;155:2113-19.
189. Irmak S, Tilki D, Heukeshoven J, et al. Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005;5:4296-304.
190. Orenes-Pinero E, Corton M, Gonzalez-Peramato P, et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel elec-trophoresis (2D-DIGE) approach. J Proteome Res 2007;6:4440-8.
191. Saito M, Kimoto M, Araki T, et al. Proteome analysis of gelatinbound urinary proteins from patients with bladder cancers. Eur Urol 2005;48:865-71.
192. Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med 2014;3:7.
193. Chung H, Kim B, Jung SH, et al. Does phosphorylation of cofilin affect the progression of human bladder cancer? BMC Cancer 2013;13:45.
194. Frantzi M, Zoidakis J, Papadopoulos T, et al. IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. J Proteome Res 2013;12: 3969-79.
195. Schiffer E, Vlahou A, Petrolekas A, et al. Prediction of muscleinvasive bladder cancer using urinary proteomics. Clin Cancer Res 2009;15:4935-43.
196. Kato M, Wei M, Yamano S, et al. DDX39 acts as a suppressor of invasion for bladder cancer. Cancer Sci 2012;103:1363-9.
197. Zoidakis J, Makridakis M, Zerefos PG, et al. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics 2012;11:M111.009449.
198. Rosser CJ, Liu L, Sun Y, et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009;18:444-53.
199. Urquidi V, Goodison S, Cai Y, et al. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2149-58.
200. Yang N, Feng S, Shedden K, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011;17: 3349-59.
201. Feng S, Yang N, Pennathur S, et al. Enrichment of glycoproteins using nanoscale chelating conca-navalin A monolithic capillary chromatography. Anal Chem 2009;81:3776-83.
202. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2011;13:790-801.
203. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009;115:68-74.
204. Fajkovic H, Halpern JA, Cha EK, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29:457-63.
205. Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 2012;109:1716-26.
206. Miyamoto H, Zheng Y, Izumi K. Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Targets 2012;12:14-22.
207. Boorjian SA, Heemers HV, Frank I, et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 2009;16:123-37.
208. Zhuang YH, Blauer M, Tammela T, Tuohimaa P. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997;30:556-62.
209. Ruizeveld de Winter JA, Trapman J, Vermey M, et al. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991;39:927-36.
210. Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011;50:931-44.
211. Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004;64:383-8.
212. Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2011;29: 43-51.
213. Rau KM, Chen YJ, Sun MT, Kang HY. Prognostic effects and regulation of activin A, maspin, and the androgen receptor in upper urinary tract urothelial carcinoma. Anticancer Res 2011;31: 1713-20.
214. Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multiinstitutional study. BJU Int 2011;108:24-30.
215. Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007;99:558-68.
216. Matsushita K, Cha EK, Matsumoto K, et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol 2011;18: 616-29.
217. Bolenz C, Lotan Y, Ashfaq R, Shariat SF. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 2009;56:1093-5.
218. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-16.
219. Basakci A, Kirkali Z, Tuzel E, et al. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 2002;41:342-5.
220. Han B, Cui D, Jing Y, et al. Estrogen receptor beta (ERbeta) is a novel prognostic marker of recurrence survival in non-muscleinvasive bladder cancer potentially by inhibiting cadherin switch. World J Urol 2012;30:861-7.
221. Rizk DE, Raaschou T, Mason N, Berg B. Evidence of progesterone receptors in the mucosa of the urinary bladder. Scand J Urol Nephrol 2001;35:305-9.
222. Celayir S, Ilce Z, Dervisoglu S. The sex hormone receptors in the bladder in childhood - I: preliminary report in male subjects. Eur J Pediatr Surg 2002;12:312-17.
223. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182: 78-84.
224. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183:68-75.
225. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-25.
226. Shariat SF, Zlotta AR, Ashfaq R, et al. Cooperative effect of cellcycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20:445-59.
227. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177:481-7.
228. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008;18:1-8.
229. Kattan MW. Nomograms. Introduction. Semin Urol Oncol 2002; 20:79-81.
230. Specht MC, Kattan MW, Gonen M, et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005;12:654-9.
231. Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010; 280:389-400.
232. Bryan RT, Collins SI, Daykin MC, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 2010; 92:519-24.
233. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006;50:1254-60.
234. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967-72.
235. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006;12:6663-76.
236. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006;176:1354-61.
237. Zaak D, Burger M, Otto W, et al. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int 2010;106:342-8.
238. Soloway M, Khoury S, eds. Bladder cancer. Second International Consultation on Bladder Cancer-Vienna, 2nd ed., 2012.
239. Shariat SF, Zippe C, Ludecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005;173:1518-25.
240. Qureshi KN, Naguib RN, Hamdy FC, et al. Neural network analysis of clinicopathological and molecular markers in bladder cancer. J Urol 2000;163:630-3.
241. el-Mekresh M, Akl A, Mosbah A, et al. Prediction of survival after radical cystectomy for invasive bladder carcinoma: risk group stratification, nomograms or artificial neural networks? J Urol 2009;182:466-72.
242. Catto JW, Linkens DA, Abbod MF, et al. Artificial intelligence in predicting bladder cancer outcome: a comparison of neurofuzzy modeling and artificial neural networks. Clin Cancer Res 2003;9: 4172-7.
243. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009;69:8302-9.
244. Smith SC, Havaleshko DM, Moon K, et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 2011;13:72-80.
245. Goodison S, Rosser CJ, Urquidi V. Bladder cancer detection and monitoring: assessment of urine-and blood-based marker tests. Mol Diagn Ther 2013;17:71-84.
246. Xylinas E, Kluth LA, Lotan Y, et al. Blood-and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol 2014;32:230-42.
247. Ghafouri-Fard S, Nekoohesh L, Motevaseli E. Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev 2014;15: 2395-403.
248. Cheng L, Davison DD, Adams J, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 2014;89:73-111.
249. Ye F, Wang L, Castillo-Martin M, et al. Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol 2014; 2:1-14.
250. Castillejo A, Rothman N, Murta-Nascimento C, et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 2009;124:608-13.
251. Guan K-P, Ye H-Y, Yan Z, et al. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003; 61:719-23.
252. Svatek RS, Shah JB, Xing J, et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer 2010;116:4513-19.
253. Szarvas T, Becker M, vom Dorp F, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 2010;101:1300-8.
254. Szarvas T, Jager T, Becker M, et al. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res 2011;17: 325-32.
255. Andrews B, Shariat SF, Kim JH, et al. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002;167: 1475-81.
256. Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 2012;61:810-17.
257. Gazzaniga P, Gradilone A, de Berardinis E, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a cell search analysis. Ann Oncol 2012;23:2352-6.
258. Schultz IJ, Wester K, Straatman H, et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007;51:416-22.
259. Ito M, Nishiyama H, Kawanishi H, et al. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J Urol 2007;178:1073-9.
260. Holyoake A, O'Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008; 14:742-9.
261. Gazzaniga P, Gradilone A, de Berardinis E, et al. A chemosensitivity test to individualize intravesical treatment for non-muscleinvasive bladder cancer. BJU Int 2009;104:184-8.
262. Kim YJ, Ha YS, Kim SK, et al. Gene signatures for the prediction of response to bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 2010;16:2131-7.
263. Kim YH, Kim WT, Jeong P, et al. Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2. J Korean Med Sci 2014;29:351-6.
264. Mengual L, Ribal MJ, Lozano JJ, et al. Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models. J Urol 2014;191: 261-9.